Travere Therapeutics, Inc. (TVTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US89422G1076
Travere Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 490.73 m USD |
| Gross profit | 480.39 m USD |
| Operating income | -62.82 m USD |
| EBIT | -26.53 m USD |
| Net income | -25.55 m USD |
| Diluted EPS – continuing operations | -0.29 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
More stocks
- PCCW Ltd (8.HK)
- Fortune Brands Innovations, Inc. (FBIN)
- Global Business Travel Group, Inc. (GBTG)
- Nova Ljubljanska Banka d.d. (NLBR.VI)
- Beijing Enlight Media (300251.SZ)
- Hanwha Solutions (009830.KS)
- Mirvac Group (MGR.AX)
- Kodiak Gas Services, Inc. (KGS)
- TOTVS S.A (TOTS3.SA)
- Vend Marketplaces ASA (VEND.OL)
- Yonyou Network Technology Co Ltd (600588.SS)
- Golar LNG Ltd (GLNG)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.